World Library  
Flag as Inappropriate
Email this Article

Cyclin A2

Article Id: WHEBN0014218913
Reproduction Date:

Title: Cyclin A2  
Author: World Heritage Encyclopedia
Language: English
Subject: Postreplication checkpoint, Cellular apoptosis susceptibility protein, CDC6, CDKN2D, Cyclin B2
Collection: Cell Cycle
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Cyclin A2

Cyclin A2

PDB rendering based on 1e9h.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols  ; CCN1; CCNA
External IDs ChEMBL: GeneCards:
RNA expression pattern
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)
RefSeq (protein)
Location (UCSC)
PubMed search

Cyclin-A2 is a protein that in humans is encoded by the CCNA2 gene.[1] It is one of the two types of cyclin A: cyclin A1 is expressed during meiosis and embryogenesis while cyclin A2 is expressed in dividing somatic cells.[2]

Contents

  • Function 1
  • Regulation 2
  • Interactions 3
  • Clinical significance 4
  • Cancer 5
  • See also 6
  • References 7
  • Further reading 8

Function

Cyclin A2 belongs to the cyclin family, whose members regulate cell cycle progression by interacting with CDK kinases. Cyclin A2 is unique in that it can activate two different CDK kinases; it binds CDK2 during S phase, and CDK1 during the transition from G2 to M phase.[3]

Cyclin A2 is synthesized at the onset of S phase and localizes to the nucleus, where the cyclin A2-CDK2 complex is implicated in the initiation and progression of DNA synthesis. Phosphorylation of CDC6 and MCM4 by the cyclin A2-CDK2 complex prevents re-replication of DNA during the cell cycle.[2]

Cyclin A2 is involved in the G2/M transition but it cannot independently form a maturation promoting factor (MPF).[4] Recent studies have shown that the cyclin A2-CDK1 complex triggers cyclin B1-CDK1 activation which results in chromatin condensation and the breakdown of the nuclear envelope.[5]

Regulation

The levels of cyclin A2 are tightly synchronized with the progression of the cell cycle.[6] Transcription initiates in late G1, peaks and plateaus in mid-S, and declines in G2.[6][7]

Cyclin A2 transcription is mostly regulated by the transcription factor E2F and begins in G1, after the R point.[6][7] Absence of cyclin A2 before the R point is due to the E2F inhibition by hypophosphorylated retinoblastoma protein (pRb). After the R point, pRb is phosphorylated and can no longer bind E2F, leading to cyclin A2 transcription.[8][9] The cyclin A2-CDK2 complex eventually phosphorylates E2F, turning off cyclin A2 transcription.[6] E2F promotes cyclin A2 transcription by de-repressing the promoter.[6][8]

Interactions

Cyclin A2 has been shown to interact with:


Clinical significance

Cyclin A2 (Ccna2) is a key protein involved in the direction of mammalian cardiac myocytes to grow and divide, and has been shown to induce cardiac repair following myocardial infarction.[18] Normally, Ccna2 is silenced postnatally in mammalian cardiac myocytes. Because of this gene silencing, adult heart muscle cells cannot divide readily to repair and regenerate after a heart attack.[18]

Ccna2 has been found to induce cardiac repair in small-animal models following myocardial infarction.[18] Preclinical trials involving injections of adenovirus which contained the Ccna2 gene into infarcted porcine (pig) hearts has shown to be protective of MI in pig hearts.[18] Ccna2 mediated cardiac repair showed both a decrease in fibrosis in the peri-infarct tissue and a greater number of cardiomyocytes at the sites of injection.[18] Delivery of Ccna2 into cardiac tissue invokes a regenerative response and markedly enhances cardiac function.[18][19][20]

Cancer

Increased expression of cyclin A2 has been observed in many types of cancer such as breast, cervical, liver, and lung among others.[2][21][22][23][24] While it is not clear whether increased expression of cyclin A2 is a cause or result of tumorigenesis, it is indicative of prognostic values such as predictions of survival or relapse.[2]

Overexpresssion of cyclin A2 in mammalian cells can result in the delayed onset of metaphase and anaphase.[25] It is also possible that cyclin A2-CDK contributes to tumorigenesis by the phosphorylation of oncoproteins or tumor suppressors like p53.[26]

See also

References

  1. ^ Paterlini P, De Mitri MS, Martin C, Munnich A, Brechot C (July 1991). "A Taql polymorphism in the human cyclin A gene". Nucleic Acids Res 19 (9): 2516.  
  2. ^ a b c d Yam CH, Fung TK, Poon RY (Aug 2002). "Cyclin A in cell cycle control and cancer". Cellular and Molecular Life Sciences 59 (8): 1317–26.  
  3. ^ Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G (March 1992). "Cyclin A is required at two points in the human cell cycle". The EMBO Journal 11 (3): 961–71.  
  4. ^ Fung TK, Ma HT, Poon RY (Mar 2007). "Specialized roles of the two mitotic cyclins in somatic cells: cyclin A as an activator of M phase-promoting factor". Molecular Biology of the Cell 18 (5): 1861–73.  
  5. ^ Gong D, Ferrell JE Jr. (Sep 2010). "The roles of cyclin A2, B1, and B2 in early and late mitotic events". Molecular Biology of the Cell 21 (18): 3149–61.  
  6. ^ a b c d e Henglein B, Chenivesse X, Wang J, Eick D, Bréchot C (Jun 1994). "Structure and cell cycle-regulated transcription of the human cyclin A gene". Proceedings of the National Academy of Sciences of the USA 91 (12): 5490–4.  
  7. ^ a b
  8. ^ a b Woo RA, Poon RY (Jul–Aug 2003). "Cyclin-dependent kinases and S phase control in mammalian cells". Cell Cycle 2 (4): 316–24.  
  9. ^ a b Xu M, Sheppard KA, Peng CY, et al. (1994). "Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation". Mol. Cell. Biol. 14 (12): 8420–31.  
  10. ^ Petersen BO, Lukas J, Sørensen CS, Bartek J, Helin K (January 1999). "Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization". EMBO J. 18 (2): 396–410.  
  11. ^ Saha P, Chen J, Thome KC, Lawlis SJ, Hou ZH, Hendricks M, Parvin JD, Dutta A (May 1998). "Human CDC6/Cdc18 associates with Orc1 and cyclin-cdk and is selectively eliminated from the nucleus at the onset of S phase". Mol. Cell. Biol. 18 (5): 2758–67.  
  12. ^ Henneke G, Koundrioukoff S, Hübscher U (July 2003). "Phosphorylation of human Fen1 by cyclin-dependent kinase modulates its role in replication fork regulation". Oncogene 22 (28): 4301–13.  
  13. ^ Ohtoshi A, Maeda T, Higashi H, Ashizawa S, Yamada M, Hatakeyama M (January 2000). "beta3-endonexin as a novel inhibitor of cyclin A-associated kinase". Biochem. Biophys. Res. Commun. 267 (3): 947–52.  
  14. ^ Dyson N, Dembski M, Fattaey A, Ngwu C, Ewen M, Helin K (December 1993). "Analysis of p107-associated proteins: p107 associates with a form of E2F that differs from pRB-associated E2F-1". J. Virol. 67 (12): 7641–7.  
  15. ^ Joaquin M, Bessa M, Saville MK, Watson RJ (November 2002). "B-Myb overcomes a p107-mediated cell proliferation block by interacting with an N-terminal domain of p107". Oncogene 21 (52): 7923–32.  
  16. ^ Rosner M, Hengstschläger M (November 2004). "Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2". J. Biol. Chem. 279 (47): 48707–15.  
  17. ^ Marti A, Wirbelauer C, Scheffner M, Krek W (May 1999). "Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation". Nat. Cell Biol. 1 (1): 14–9.  
  18. ^ a b c d e f Shapiro SD, Ranjan AK, Kawase Y, Cheng RK, Kara RJ, Bhattacharya R, Guzman-Martinez G, Sanz J, Garcia MJ, Chaudhry HW (2014). "Cyclin A2 induces cardiac regeneration after myocardial infarction through cytokinesis of adult cardiomyocytes". Sci Transl Med 6 (224): 224ra27.  
  19. ^ Woo YJ, Panlilio CM, Cheng RK, Liao GP, Suarez EE, Atluri P, Chaudhry HW (2007). "Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2". J. Thorac. Cardiovasc. Surg. 133 (4): 927–33.  
  20. ^ Laflamme MA, Murry CE (2011). "Heart regeneration". Nature 473 (7347): 326–35.  
  21. ^ Bukholm IR, Bukholm G, Nesland JM (Jul 2001). "Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas". International Journal of Cancer 93 (2): 283–7.  
  22. ^ Kanai M, Shiozawa T, Xin L, Nikaido T, Fuiji S (May 1998). "Immunohistochemical detection of sex steroid receptors, cyclins, and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix". Cancer 82 (9): 1709–19.  
  23. ^ Ohashi R, Gao C, Miyazaki M, Hamazaki K, Tsuji T, Inoue Y, Uemura T, Hirai R, Shimizu N, Namba M (Jan–Feb 2001). "Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas.". Anticancer Research 21 (1B): 657–62.  
  24. ^ Volm M, Koomägi R, Mattern J, Stammler G (1997). "Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas". British Journal of Cancer 75 (12): 1774–8.  
  25. ^ den Elzen N, Pines J (Apr 2001). "Cyclin A is destroyed in prometaphase and can delay chromosome alignment and anaphase". Journal of Cell Biology 153 (1): 121–36.  
  26. ^ Wang Y, Prives C (Jul 1995). "Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases". Nature 376 (6535): 88–91.  

Further reading

  • Bailly E, Pines J, Hunter T, Bornens M (1992). "Cytoplasmic accumulation of cyclin B1 in human cells: association with a detergent-resistant compartment and with the centrosome". J. Cell. Sci. 101 (3): 529–45.  
  • Faha B, Ewen ME, Tsai LH, et al. (1992). "Interaction between human cyclin A and adenovirus E1A-associated p107 protein". Science 255 (5040): 87–90.  
  • Bandara LR, Adamczewski JP, Hunt T, La Thangue NB (1991). "Cyclin A and the retinoblastoma gene product complex with a common transcription factor". Nature 352 (6332): 249–51.  
  • Blanquet V, Wang JA, Chenivesse X, et al. (1991). "Assignment of a human cyclin A gene to 4q26-q27". Genomics 8 (3): 595–7.  
  • Wang J, Chenivesse X, Henglein B, Bréchot C (1990). "Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma". Nature 343 (6258): 555–7.  
  • Jeffrey PD, Russo AA, Polyak K, et al. (1995). "Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex". Nature 376 (6538): 313–20.  
  • Castro A, Jaumot M, Vergés M, et al. (1994). "Microsomal localization of cyclin A and cdk2 in proliferating rat liver cells". Biochem. Biophys. Res. Commun. 201 (3): 1072–8.  
  • Dyson N, Dembski M, Fattaey A, et al. (1993). "Analysis of p107-associated proteins: p107 associates with a form of E2F that differs from pRB-associated E2F-1". J. Virol. 67 (12): 7641–7.  
  • Li Y, Graham C, Lacy S, et al. (1994). "The adenovirus E1A-associated 130-kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E". Genes Dev. 7 (12A): 2366–77.  
  • Lees EM, Harlow E (1993). "Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase". Mol. Cell. Biol. 13 (2): 1194–201.  
  • Sebastian B, Kakizuka A, Hunter T (1993). "Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15". Proc. Natl. Acad. Sci. U.S.A. 90 (8): 3521–4.  
  • Carbonaro-Hall D, Williams R, Wu L, et al. (1993). "G1 expression and multistage dynamics of cyclin A in human osteosarcoma cells". Oncogene 8 (6): 1649–59.  
  • Meikrantz W, Schlegel R (1996). "Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases". J. Biol. Chem. 271 (17): 10205–9.  
  • Poon RY, Jiang W, Toyoshima H, Hunter T (1996). "Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage". J. Biol. Chem. 271 (22): 13283–91.  
  • Russo AA, Jeffrey PD, Patten AK, et al. (1996). "Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex". Nature 382 (6589): 325–31.  
  • Russo AA, Jeffrey PD, Pavletich NP (1996). "Structural basis of cyclin-dependent kinase activation by phosphorylation". Nat. Struct. Biol. 3 (8): 696–700.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.